# A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

> **NCT05057013** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Research UK** · enrollment: 81 (estimated)

## Conditions studied

- Bladder Cancer
- Triple Negative Breast Cancer
- Castration-resistant Prostate Cancer
- Cervical Cancer
- RAS Wild Type Colorectal Cancer
- Endometrial Cancer
- Gastric Cancer
- Hepatocellular Carcinoma (HCC)
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Oesophageal Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Squamous Cell Cancer of the Head and Neck

## Interventions

- **DRUG:** HMBD-001
- **DRUG:** HMBD-001 and enzalutamide

## Key facts

- **NCT ID:** NCT05057013
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-10
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057013, "A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05057013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*